Executive Summary
Lockheed Martin's $20.65B cost-plus contract for Y-12 plant management through 2027 delivers unmatched revenue visibility in DOE facilities operations. The fully funded structure (minimal gap between obligation and base+options) signals high stability for aerospace & defense. Zero outlays despite 43-year history flags execution risks tied to DOE budgets, prioritizing funding monitoring.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from February 28, 2026.
Investment Signals (1)
- $20.65B Long-Term DOE Y-12 Contract Stability (HIGH)▲
Definitive award via full competition provides cost-plus revenue through Feb 2027 with near-fully funded $20.646B obligation.
Risk Flags (2)
- Execution [HIGH RISK]▼
$0 outlays on $20.65B obligation despite ongoing performance to 2027 indicate potential delays.
- Market [MEDIUM RISK]▼
Cost-plus reliance on DOE budgets exposes to federal funding uncertainties post-2027.
Opportunities (1)
- ◆
Follow-on Y-12 work beyond 2027 leveraging incumbent status in full/open competition.
Sector Themes (1)
- ◆
43-year cost-plus awards to non-small corporates like Lockheed highlight DOE preference for stable operators in R&D facilities (NAICS 561210).
Watch List (2)
- 👁
{"entity"=>"Lockheed Martin Y-12 Contract Outlays", "reason"=>"Zero funding on $20.65B obligation atypical for mature award.", "trigger"=>"First outlays >$10M or cessation announcements"}
- 👁
{"entity"=>"DOE SC Oak Ridge Budget", "reason"=>"Drives reimbursements and 2027+ extensions.", "trigger"=>"Cuts >10% or supplemental funding"}
Get daily alerts with 1 investment signals, 2 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Significant Contract Modifications ($10M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
US Pre-Market SEC Filings Roundup — May 26, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
Biotech Small-Cap Approvals — May 26, 2026
Biotech Small-Cap Approvals
May 26, 2026
Big Pharma Approvals — May 26, 2026
Big Pharma Approvals